NYSE : AFT
-$0.05 (-0.34%)
| Source | Headline |
|---|---|
|
FDA Approves Pfizer's IBRANCE Regimen for HR+, HER2+ Metastatic Breast Cancer Frontline Maintenance
Pfizer Inc. (NYSE: PFE) today announced the U.S. Food and Drug Administration (FDA) approved IBRANCEÂ (palbociclib) in combination with trastuzumab, with or w gurufocus.com - 2026-06-24 15:00:00 |